Healthcare industry reported 70 deals worth $6.2 billion in January 2021: GlobalData

In January 2021, the healthcare industry reported 70 deals worth $6.2 billion as compared to last 12-month average (January 2020 to December 2020) of 87 deals worth $17.1 billion.

Sanofi, a pharma company to acquire Kymab, a clinical-stage biopharma company focusing on developing fully human monoclonal antibody therapeutics for approximately $1.4 billion; Angelini Pharma, a pharma company to acquire Arvelle Therapeutics, a biopharma company for $960 million; Thermo Fisher Scientific, to acquire Henogen S.A., a biotech company for $880.8 million and Nordic Capital, to acquire Advanz Pharma Corp, a pharma company for $846 million were some of the major deals that contributed 66 per cent of the total deal value during January 2021.

VC investments decreased by three per cent in January 2021, compared to December 2020

The healthcare industry reported 77 venture capital (VC) deals worth $4.4 billion in January 2021, compared to last 12-month average (January 2020 to December 2020) of 124 deals worth $3.2 billion.

EQRx, a biotechnology company raising $500 million in series B financing round for the development of late-stage cancer therapies, pipeline expansion and business growth; Affinivax, a clinical stage biopharma company raising $226 million in series C round of financing to advance its pipeline of Novel MAPS vaccines targeting infectious diseases and New Amsterdam Pharma, a clinical stage company raising $196 million in series A round of financing to support the Phase 3 development of its ApoB and LDL-c lowering small molecule drug—obicetrapib—are the major VC deals reported in January 2021.